To become a transcendent leader, we must understand what truly motivates people.
Author and leadership expert Fred Kofman believes there are four levers leaders must utilize to capture the hearts and minds of their team members.
Yesterday, we looked at the power of purpose. Today, we detail three other powerful tools transcendent leaders tap into to build inspired organizations: Principles, People, and Autonomy.
First up: Principles.
“As a culture architect,” … continue reading
1: Michi, Fred Kofman‘s then seven-year-old daughter, saw him packing for a business trip.
“Please, Daddy, don’t go,” she begged.
“I was tempted,” Fred recalls in his book The Meaning Revolution, “to give her a perfunctory and dismissive response like ‘I wish I could, sweetie, but Daddy has to work.'”
But that’s not what he said. Fred paused for a moment. He would be traveling to the headquarters … continue reading
1: “Eliciting people’s internal commitment to pursue a common goal is the job of every leader,” writes Fred Kofman in his terrific book The Meaning Revolution: The Power of Transcendent Leadership.
We seek “the internal commitment of our followers to pursue a common goal, giving the best of themselves because they want to, because they find it intrinsically valuable beyond external incentives.”
So how do we do that?
“By … continue reading
1: Monday through Thursday, we explore ideas from authors, thought leaders, and exemplary organizations. On Friday, I share something about myself or what we are working on at PCI.
Searching for a bit of wisdom as we push to end 2024 on a solid note and start 2025 with a bang? Read on!
Imagine we adopt a new puppy from the pet shop, suggests Peter D. Kaufman, CEO … continue reading
1: James Clear‘s book Atomic Habits has sold over 20 million copies worldwide.
“To put this in proper perspective,” Dan Sullivan and Benjamin Hardy write in 10x Is Easier Than 2x, “out of the millions of books published each year, less than 20 will go on to sell over one million copies. The average U.S. book sells less than 200 copies per year and less than 1,000 … continue reading
1: The year was 2002. Chad Willardson was one of 100 trainees who started the financial advisor training at Merrill Lynch in Southern California. He was 24 years old.
The success metric was clear: Achieve $15 million under management within 18 months or be fired.
“It was a brutal and intense growth curve,” Dan Sullivan and Benjamin Hardy write in 10x Is Easier Than 2x: How World-Class Entrepreneurs Achieve More … continue reading
1: Imagine our goal is to raise $10 million.
Which is a better approach? Would we rather solve 100 problems at $100,000 each?
Or, attempt to solve a single $30 million problem?
Dr. Alan Barnard, one of the world’s leading experts on constraint theory and decision-making, believes the second approach is a far better strategy.
Why? “For multiple reasons,” Alan believes, as quoted by Dan Sullivan and Ben Hardy… continue reading
“Every next level of your life will require a different you.” -Leonardo DiCaprio
1: Most people get stuck in a 2x mindset. They struggle to manifest 10x in their lives.
They have it backward, Dan Sullivan and Benjamin Hardy write in 10x Is Easier Than 2x: How World-Class Entrepreneurs Achieve More by Doing Less.
When we choose a 2x goal, we choose “doing the same things we’re doing now, … continue reading
1: Getting better at getting better is what RiseWithDrew is all about.
Monday through Thursday, we explore ideas from authors, thought leaders, and exemplary organizations. On Friday, I share something about myself or what we are working on at PCI.
Searching for a bit of wisdom as we push to end 2024 on a strong note and start 2025 with a bang.
How does everything in the world work?
There … continue reading
1: The wife of a close friend of Dr. Peter Attia was diagnosed with breast cancer.
“Sandra (not her real name) had been diagnosed with breast cancer six years earlier,” Peter writes in his book Outlive. “It had already spread to her lymph nodes and her bones. Because of her poor prognosis, she qualified for a clinical trial of an experimental PI3K-inhibitor drug, in combination with standard therapies.”
What … continue reading
